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stenosis despite a conservative approach to asymptomatic carotid
disease, in keeping with previous studies.1,4 Following a transient
ischemic attack, patients require duplex scanning after the event to
direct their management. Thus, for patients in whom a conserva-
tive approach is to be applied to asymptomatic restenosis or pro-
gression of contralateral disease, the value of duplex surveillance is
limited to research and audit. To clearly demonstrate a value of
duplex surveillance following carotid surgery would require an
appropriately powered randomized trial. Possibly more useful than
duplex surveillance might be the identification of biomarkers,
genetic markers or new imaging techniques that better identify
presently asymptomatic patients likely to experience a stroke.5,6
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Reply
We appreciate professor Golledge’s comments on one of the
more controversial issues concerning patients who undergo carotid
surgery—ie, the utility of ultrasound surveillance to manage the
progression of contralateral asymptomatic carotid disease.1
Golledge asserts that “an imaging finding is primarily of value
if it alters the clinical management of the patient.” Therefore,
taking Golledge’s words literally, because diabetic patients (being
at high vascular risk, according to current guidelines) are given
antiplatelet therapy, they should not have duplex ultrasonography
(DUS) until they suffer a stroke or other cardiovascular event,
because it is only then that a change of treatment would be
recommended—a bit late, in our opinion. According to the results
of the major randomized clinical trials, DUS follow-up would at
least pinpoint patients progressing to severe asymptomatic carotid
disease and likely to benefit from carotid endarterectomy. Contrar-
ily to the previous statement, Golledge himself admits that DUS
can noninvasively detect patients with complications potentially
hazardous to their health if not properly treated.
Golledge says that “ipsilateral restenosis. . .is believed to have a
benign natural history and therefore many clinicians treat such lesions
medically.”2 But how do we identify ipsilateral restenosis without
proper imaging? And how can the benign nature of such lesion be
established without a proper follow-up, including clinical assessment
and instrumental evaluation (DUS is the cheapest and safest method
available)?
The meta-analyses that Golledge mentions3,4 demonstrate that,
in expert hands, patients (especially men) with stenosis greater than
60% clearly benefit from carotid endarterectomy; considering the
burden of stroke on a patient and the community, we are sure
Golledge would agree on the merits of avoiding even a single stroke.
We agree that an appropriately powered randomized trial
would be preferable to our large but single-center study, and we
would be happy to collaborate with professor Golledge to set up
such a trial. Every patient deserves the best possible management,
wherever they live, which is why DUS (which is readily available
everywhere, cheap, and noninvasive) is useful in such a context (the
same can be hardly be said for the high-resolution, ultrasmall,
superparamagnetic iron oxide–enhanced magnetic resonance im-
aging5). We know of no specific biomarkers or genetic markers
capable of reliably identifying asymptomatic patients likely to
experience a stroke: C-reactive protein is one of many biomarkers
being studied as a predictor of cardiovascular events in patients
with carotid stenosis6, but it is aspecific for stroke, and the research
has been conducted on patients taking platelet inhibitors and/or
statins, which influence not only the occurrence of cardiocerebro-
vascular events but also the levels of acute-phase inflammatory
parameters such as C-reactive protein.
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Regarding “EXCLUDER trial events are excluded
from EXCLUDER trial report”
We read with interest the article of Peterson et al,1 which
reported 5-year data from a controlled trial of the EXCLUDER
device for endovascular repair (EVAR) of abdominal aortic aneu-
rysms but are concerned that their conclusions are not supported
by the presented data. The study was nonrandomized, as the
investigators state, but there are other large sources of confusion.
For example, of 235 patients selected for EVAR, only 128 patients
are included with no explanation of what happened to the remain-
ing 107 patients. Furthermore, though the investigator’s defini-
tion of adverse events is given in text, there is no description of
what these events actually were, who adjudicated them, or whether
they were blinded. The authors show that nearly 70% of patients
treated with open repair had a major adverse event within 30 days,
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